NO902444D0 - POLYPEPTIDES. - Google Patents

POLYPEPTIDES.

Info

Publication number
NO902444D0
NO902444D0 NO902444A NO902444A NO902444D0 NO 902444 D0 NO902444 D0 NO 902444D0 NO 902444 A NO902444 A NO 902444A NO 902444 A NO902444 A NO 902444A NO 902444 D0 NO902444 D0 NO 902444D0
Authority
NO
Norway
Prior art keywords
pro
cys
lys
gly
ile
Prior art date
Application number
NO902444A
Other languages
Norwegian (no)
Other versions
NO177716B (en
NO902444L (en
NO177716C (en
Inventor
Enno Christophers
Oliver Wiedow
Jens-Michael Schroder
Michael Derek Edge
David Pioli
Original Assignee
Ici Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898913346A external-priority patent/GB8913346D0/en
Priority claimed from GB898913349A external-priority patent/GB8913349D0/en
Priority claimed from GB898921613A external-priority patent/GB8921613D0/en
Priority claimed from GB898924717A external-priority patent/GB8924717D0/en
Application filed by Ici Plc filed Critical Ici Plc
Publication of NO902444D0 publication Critical patent/NO902444D0/en
Publication of NO902444L publication Critical patent/NO902444L/en
Publication of NO177716B publication Critical patent/NO177716B/en
Publication of NO177716C publication Critical patent/NO177716C/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Polypeptides, in particular the polypeptide of formula I: Ala-Gln-Glu-Pro-Val-Lys-Gly-Pro-Val-Ser-Thr-Lys-Pro-Gly-Ser-Cys-Pro-Il e-Ile-Leu- Ile-Arg-Cys-Ala-Met-Leu-Asn-Pro-Pro-Asn-Arg-Cys-Leu-Lys-Asp-Thr-Asp-Cy s-Pro-Gly- Ile-Lys-Lys-Cys-Cys-Glu-Gly-Ser-Cys-Gly-Met-Ala-Cys-Phe-Val-Pro-Gln and analogues thereof which possess inhibitory activity against human leukocyte elastase. The polypeptides may be obtained by expression using plasmidic expression systems in hosts such as E. Coli and yeast, the polypeptide of formula I being also obtainable from psoriatic plaques.
NO902444A 1989-06-09 1990-06-01 Method for Preparation of Therapeutically Active Polypeptides, DNA Sequence, Expression Vector and Antibody NO177716C (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB898913346A GB8913346D0 (en) 1989-06-09 1989-06-09 Polypeptide analogues
GB898913349A GB8913349D0 (en) 1989-06-09 1989-06-09 Polypeptides
GB898921613A GB8921613D0 (en) 1989-09-25 1989-09-25 Polypeptides-1st update
GB898924717A GB8924717D0 (en) 1989-11-02 1989-11-02 Polypeptides

Publications (4)

Publication Number Publication Date
NO902444D0 true NO902444D0 (en) 1990-06-01
NO902444L NO902444L (en) 1990-12-10
NO177716B NO177716B (en) 1995-07-31
NO177716C NO177716C (en) 1995-11-08

Family

ID=27450350

Family Applications (1)

Application Number Title Priority Date Filing Date
NO902444A NO177716C (en) 1989-06-09 1990-06-01 Method for Preparation of Therapeutically Active Polypeptides, DNA Sequence, Expression Vector and Antibody

Country Status (16)

Country Link
US (4) US5464822A (en)
EP (1) EP0402068B1 (en)
JP (1) JP2989853B2 (en)
AT (1) ATE131493T1 (en)
AU (1) AU636148B2 (en)
CA (1) CA2018592C (en)
DE (1) DE69024104T2 (en)
DK (1) DK0402068T3 (en)
ES (1) ES2080800T3 (en)
FI (1) FI106471B (en)
GR (1) GR3018401T3 (en)
IE (1) IE70520B1 (en)
IL (1) IL94602A (en)
NO (1) NO177716C (en)
NZ (1) NZ233974A (en)
PT (1) PT94326B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO177716C (en) * 1989-06-09 1995-11-08 Zeneca Ltd Method for Preparation of Therapeutically Active Polypeptides, DNA Sequence, Expression Vector and Antibody
EP0458537B1 (en) * 1990-05-24 1999-03-31 Zeneca Limited Use of a therapeutic compound for the treatment of bronchitis
DE69129083T2 (en) * 1990-05-24 1998-07-09 Zeneca Ltd Therapeutic agent for the prevention and treatment of respiratory distress syndrome in adults
US5162348A (en) * 1990-05-24 1992-11-10 Imperial Chemical Industries Plc Treatment of cystic fibrosis
US5734014A (en) * 1992-08-11 1998-03-31 Tsumura & Co. Elafin derivative
US8606851B2 (en) 1995-06-06 2013-12-10 Wayport, Inc. Method and apparatus for geographic-based communications service
US5835061A (en) 1995-06-06 1998-11-10 Wayport, Inc. Method and apparatus for geographic-based communications service
EP0834556A1 (en) * 1996-09-25 1998-04-08 Academisch Ziekenhuis Leiden Methods for culturing cells
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU2001241913A1 (en) * 2000-03-01 2001-09-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for wound treatment
US7247704B2 (en) 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
US6600057B2 (en) 2000-12-29 2003-07-29 Kimberly-Clark Worldwide, Inc. Matrix metalloproteinase inhibitors
US7041787B2 (en) * 2000-12-29 2006-05-09 Kimberly-Clark Worldwide, Inc. Design and use of advanced zinc chelating peptides to regulate matrix metalloproteinases
US20030119073A1 (en) * 2001-12-21 2003-06-26 Stephen Quirk Sensors and methods of detection for proteinase enzymes
US20030170617A1 (en) 2002-01-28 2003-09-11 Pasloske Brittan L. Crude biological derivatives competent for nucleic acid detection
JP4651946B2 (en) * 2002-04-25 2011-03-16 ザ スクリプス リサーチ インスティテュート Treatment and prevention of pulmonary conditions
FR2849375B1 (en) * 2002-12-30 2006-10-20 Jean Noel Thorel COSMETIC COMPOSITIONS, FOR EXAMPLE FOR TREATING SKIN-INDUCED CUTANE AGING
WO2004098626A2 (en) * 2003-05-07 2004-11-18 Vib Vzw The use of a polypeptide domain of slpi to modulate the tumorigenic and metastatic potential of cancer cells
WO2006122404A1 (en) * 2005-05-16 2006-11-23 Her Majesty The Queen In Right As Represented By The Minister Of Health Trappin-2 (elafin) inhibits hiv
US7964350B1 (en) 2007-05-18 2011-06-21 Applied Biosystems, Llc Sample preparation for in situ nucleic acid analysis
EP2367954B1 (en) * 2008-12-19 2015-02-18 Life Technologies Corporation Proteinase k inhibitors, methods and compositions therefor
GB201003559D0 (en) 2010-03-03 2010-04-21 Proteo Biotech Ag Novel use of elafin
US20230285523A1 (en) * 2021-12-20 2023-09-14 Tiakis Biotech Ag Use of elafin in the treatment of covid-19

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4746729A (en) * 1986-07-30 1988-05-24 Kuettner Klaus E Cartilage-derived leukocyte elastase-inhibitor
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
ATE162931T1 (en) * 1989-02-23 1998-02-15 Blood Res Center HUMAN ELASTASE INHIBITOR
NO177716C (en) * 1989-06-09 1995-11-08 Zeneca Ltd Method for Preparation of Therapeutically Active Polypeptides, DNA Sequence, Expression Vector and Antibody

Also Published As

Publication number Publication date
IL94602A (en) 1996-06-18
IE70520B1 (en) 1996-12-11
PT94326A (en) 1991-02-08
NO177716B (en) 1995-07-31
US6893843B2 (en) 2005-05-17
JPH03148299A (en) 1991-06-25
EP0402068A1 (en) 1990-12-12
ES2080800T3 (en) 1996-02-16
US6245739B1 (en) 2001-06-12
DK0402068T3 (en) 1996-04-22
AU636148B2 (en) 1993-04-22
IE902006L (en) 1990-12-09
CA2018592A1 (en) 1990-12-09
NO902444L (en) 1990-12-10
FI902880A0 (en) 1990-06-08
US20060068480A1 (en) 2006-03-30
DE69024104D1 (en) 1996-01-25
PT94326B (en) 1997-01-31
US5464822A (en) 1995-11-07
NO177716C (en) 1995-11-08
GR3018401T3 (en) 1996-03-31
ATE131493T1 (en) 1995-12-15
JP2989853B2 (en) 1999-12-13
CA2018592C (en) 2002-08-27
IL94602A0 (en) 1991-04-15
DE69024104T2 (en) 1996-06-13
EP0402068B1 (en) 1995-12-13
NZ233974A (en) 1993-05-26
FI106471B (en) 2001-02-15
AU5680890A (en) 1990-12-13
US20020187535A1 (en) 2002-12-12

Similar Documents

Publication Publication Date Title
NO902444D0 (en) POLYPEPTIDES.
DE69030582D1 (en) PRODUCTION OF A RECOMBINANT HUMAN INTERLEUKIN-1 INHIBITOR
DK0592566T3 (en) IL-6 muteins with reduced cysteine number
EP0225020A3 (en) Peptides comprising, in sequence, units selected from the amino-acid residues 17 to 24 of vip
ATE110742T1 (en) PEPTIDE COMPOUNDS.
ATE240398T1 (en) POLYPEPTIDE ENCODED BY KAPOSI SARCOMA ASSOCIATED HERPES VIRUS (KSHV,HHV-8) AND ITS USE IN DIAGNOSTICS AND THERAPY
CA2118498A1 (en) A novel anti-neoplastic cytokine
ATE94168T1 (en) PEPTIDES.
ATE81591T1 (en) INTERLEUKIN-2 INDUCED ANTINEOPLASTIC PEPTIDE.
DE60138885D1 (en) POLYPEPTIDES WITH THE ACTIVITY OF STIMULATION OF NEUTROPHILES
AU7052291A (en) Genetic protection of animals against infection by the bovine leukemia virus, and provirus and recombinant virus derived from this virus
IT221319Z2 (en) MULTI-PURPOSE SHELF OF THE PERFECT TYPE.
NO893283D0 (en) Disposable spray gun with built-in cannula.
CA2090121A1 (en) Uses of colony stimulating factor-1

Legal Events

Date Code Title Description
MK1K Patent expired